VPZ Plans to Open 23 New Stores by 2024

Business by 2FIRSTS.ai
Feb.22.2024
VPZ Plans to Open 23 New Stores by 2024
British e-cigarette retailer VPZ plans to open 23 new stores by mid-2024, bringing total locations to nearly 200.

According to sources from Insider, the British e-cigarette retailer VPZ, headquartered in Edinburgh, plans to open 23 new stores by mid-2024. This expansion will bring the total number of stores for the retailer to nearly 200.

 

These new stores will be located throughout England, Wales, and Scotland, offering professional smoking cessation advice, as well as sustainable products and recycling services.

 

This expansion plan will include opening 19 new flagship stores in pedestrian streets and shopping centers, as well as planning to open four new franchise stores through new and old partners, including in locations such as Cardiff, Bristol, Plymouth, Sterling, and Exeter.

 

VPZ claims to have helped approximately 700,000 smokers quit since its establishment in 2012. Managing Director of VPZ, Doug Mutter, stated:

 

We plan to open 23 new stores in the middle of this year, reflecting our desire to help more smokers start their journey to quitting smoking and properly address the environmental impact of disposable e-cigarettes.

 

Mr. Mutt supports the ban on disposable e-cigarettes, but he warns that the UK government needs to learn from similar actions in Australia, which led to the growth of an illegal black market.

 

According to reports, VPZ was founded in 2012 and currently has over 160 stores. It claims to be the largest e-cigarette retailer in the UK.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
IQOS Japan Introduces Multiple Pastel-Style UV-Printed Designs for ILUMA i, Available Until April 20
IQOS Japan Introduces Multiple Pastel-Style UV-Printed Designs for ILUMA i, Available Until April 20
The official IQOS Japan Instagram account posted that IQOS ILUMA i has introduced multiple exterior designs featuring pastel-style UV prints (a UV-curing printing process), adding spring colors to the regular device lineup, with limited-time sales at IQOS Stores through April 20.
Apr.10 by 2FIRSTS.ai
South Korea Set to Enforce Liquid Vape Ban in Smoke-Free Areas, but Welfare Ministry Abruptly Adds Two-Month Guidance Period
South Korea Set to Enforce Liquid Vape Ban in Smoke-Free Areas, but Welfare Ministry Abruptly Adds Two-Month Guidance Period
Local governments across South Korea recently issued press releases saying they would intensively crack down on the use of liquid e-cigarettes in smoke-free areas. Since the revised Tobacco Business Act, passed in December last year, included liquid e-cigarettes within the definition of tobacco and took effect on April 24, local authorities had prepared to begin enforcement immediately.
Apr.27 by 2FIRSTS.ai
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
A court declaration signed by FDA official Melanie M. Keller on March 24, 2026 detailed the status of previously issued reduction-in-force notices affecting employees at the Center for Tobacco Products (CTP).
Apr.01 by 2FIRSTS.ai
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Center for Tobacco Products Acting Director Bret Koplow issued a statement on May 7 outlining new steps to accelerate tobacco product premarket application review. The statement said CTP reduced the backlog of applications by approximately 70% in 2025 and that there is no longer a queue for PMTAs pending acceptance review.
May.09 by 2FIRSTS.ai